Application of the ICE-T Postoperative Multimodal Pain Regimen to Laparoscopic Hysterectomy

Sponsor
Mercy Research (Other)
Overall Status
Terminated
CT.gov ID
NCT04137770
Collaborator
(none)
18
1
2
25.1
0.7

Study Details

Study Description

Brief Summary

This is a randomized controlled trial evaluating whether application of ice packs and scheduled ketorolac to the surgical site after laparoscopic hysterectomy reduces need for narcotic medications.

Condition or Disease Intervention/Treatment Phase
  • Other: Ice pack and ketorolac
N/A

Detailed Description

Patients who undergo laparoscopic hysterectomy and chose to participate in the study will be randomized to either receive the standard post-surgical analgesic protocol (control group) or the standard post-surgical analgesic protocol plus scheduled ketorolac and surgical site ice packs. Usage of narcotic analgesics for breakthrough pain will be monitored and compared between cohorts. All care received by test subjects will be standard of care, with the only difference being the use of ice packs and scheduled ketorolac.

Study Design

Study Type:
Interventional
Actual Enrollment :
18 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Application of the ICE-T Postoperative Multimodal Pain Regimen to Laparoscopic Hysterectomy
Actual Study Start Date :
Feb 4, 2020
Actual Primary Completion Date :
Feb 1, 2021
Actual Study Completion Date :
Mar 8, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: control

Patients will receive routine post-operative analgesics

Experimental: intervention

Patients will receive routine post-operative analgesics plus scheduled ketorolac and surgical site ice packs

Other: Ice pack and ketorolac
Scheduled IV ketorolac will be administered and ice packs will be applied to the surgical site

Outcome Measures

Primary Outcome Measures

  1. Opioid analgesic usage in the 24 hours immediate post-operative period [24 hours]

    Opioid analgesic usage in the 24 hours immediately post-operative as measured in Morphine Milligram Equivalents

Secondary Outcome Measures

  1. Opioid analgesic usage for 6 weeks post-operative [6 weeks]

    Opioid analgesic usage for 6 weeks post-operative as measured in Morphine Milligram Equivalents

  2. Pain scores in the 24 hours immediate post-operative period [24 hours]

    Pain scores (on a scale of 1-10, 10 being worse pain) as documented by the floor nurse in the patient's chart in the 24 hours immediate post-operative period

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

Females, 18-65 years old at time of new patient evaluation, Planned laparoscopic hysterectomy only or hysterectomy with or without unilateral or bilateral oophorectomy or salpingo-oophorectomy by Dr. Corey Wagner, Uterus with expected size greater than 250 grams as determined by bimanual exam or standard of care ultrasound obtained prior to or as part of new patient evaluation

Exclusion Criteria:

Diagnosed or suspected endometriosis, Diagnosis of malignant carcinoma of the uterus, ovaries, or fallopian tubes, Diagnosis of severe renal disease (as determined by a GFR of less than 45), Known nonsteroidal anti-inflammatory drug (NSAID) intolerance, History of myocardial infarction, stroke or other cardiovascular disease, Known hypersensitivity or allergic reactions to Acetaminophen, Toradol, Ibuprofen, other NSAIDs, Aspirin or Roxicodone, Previous diagnosis of liver disease or hepatitis, Unable to take Tylenol (acetaminophen), Pre-existing narcotic drug regimens or opioid use disorders, Known diagnosis of or history of peptic ulcer disease, gastrointestinal bleeding or perforation, Known or suspected gastrointestinal obstruction including paralytic ileus, Diagnosis of severe bronchial asthma, Known diagnosis or history of cerebrovascular bleeding, Known bleeding disorder or coagulopathy based on patient history unless excluded by appropriate hematological examination, Daily prescription NSAID use, Adults unable to consent, Pregnancy as determined by urine or serum pregnancy test obtained in women of child-bearing age, Prisoners, Individuals who do not read and understand English

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mercy Hospital St. Louis Saint Louis Missouri United States 63141

Sponsors and Collaborators

  • Mercy Research

Investigators

  • Principal Investigator: Corey A Wagner, MD, Mercy St. Louis

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mercy Research
ClinicalTrials.gov Identifier:
NCT04137770
Other Study ID Numbers:
  • 20-002
First Posted:
Oct 24, 2019
Last Update Posted:
Apr 8, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 8, 2022